Clinical Trial Update: A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease [Phase 2]

View source ↗

Summary

Phase 2 dose regimen study of BRM421 Ophthalmic Solution for Dry Eye Disease and Keratoconjunctivitis Sicca is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease
• Keratoconjunctivitis Sicca

Drugs mentioned

• BRM421 Ophthalmic Solution (BRM421)

Snippet

Sponsor: BRIM Biotechnology Inc. | Conditions: Dry Eye Disease (DED), Keratoconjunctivitis Sicca | Phase 2 | Status: NOT_YET_RECRUITING